NEW YORK, NY, Jan. 03, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – DarkPulse, Inc. (OTC: DPLS) announced that, through a wholly-owned subsidiary, it has entered a License Agreement with Battelle Memorial Institute (Battelle), which operates the Pacific Northwest National Laboratory (PNNL) under contract for the US Department of Energy (DOE), providing DarkPulse with access to patents covering explosive detection, illicit drug detection, and chemical warfare agents detection technologies.

DarkPulse is developing plans to commercialize this patented technology under its Ultra-High Sensitivity Sensors (UHSS) Group.  It is the goal to develop these new products for markets seeking another level of security detecting (at orders of magnitude better sensitivity) trace amounts of explosives, chemical warfare agents (CWAs) and illicit drugs—the "Holy Grail" of global security.  The License Agreement provides DarkPulse with exclusive rights to the CWA patents when combined with a quadrupole or ion trap mass spectrometer, or with an ion mobility spectrometer.

Low-level detection of illicit substances, including explosives, narcotics, and CWAs, remains a long-standing goal of governments, the military, as well as the private sector.  For example, detection of drugs at ultra-low levels, significantly below those currently detected by state-of-the-art instrument systems analyzing swipe samples, could enable vapor detection that would supersede the detection capability of current methods.  Such systems would enable detection of vapors to identify illicit drugs in cargo containers and other concealed conveyances. Additionally, ultra-low-level detection of CWAs could also allow identification of hazardous compounds at levels well below those of today.

About DarkPulse Inc.

DarkPulse, Inc. is comprised of two, patent security platforms: Advanced, Fiber-based Monitoring Systems and Ultra-High Sensitivity Sensors ("UHSS").  The first involves advanced laser-based monitoring systems, including hardware/software that detects changes in the structural integrity of infrastructure. The second involves analytical equipment/patented technologies for detecting trace amounts of explosives, chemical warfare agents, and illicit drugs. 

For more information, visit 

Safe Harbor Statement

The information in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering, development and/or manufacturing programs, changes in product mix, development and production delays, and other factors beyond the Company's control. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

David D Singer